Hyperfine and NVIDIA Collaborate to Revolutionize Neuroimaging with AI-Powered Innovation
Collaboration aims to make portable MRI faster, smarter, and more accessible worldwide.
The AI-powered Swoop® portable MR brain imaging system.
GUILFORD, Conn.–(BUSINESS WIRE)–Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced a strategic collaboration with NVIDIA. This collaboration leverages NVIDIA AI expertise and accelerated computing to enhance Hyperfine portable imaging technology—making brain MRI faster, smarter, and more affordable on a global scale.
Brain diseases affect over three billion people worldwide1, with conditions such as stroke and neurodegenerative disorders responsible for significant mortality, disability, and economic burden. However, 90% of the global population lacks access to timely MRI diagnostics2 due to the high cost and infrastructure demands of conventional MRI systems. Hyperfine transforms this paradigm with its AI-powered portable MR technology. Designed for use at the point of care in professional healthcare settings by any trained clinician, it addresses critical healthcare gaps that conventional MRI systems cannot fill.
The collaboration between Hyperfine and NVIDIA will focus on advancing AI-powered image reconstruction and embedding real-time clinical decision support into portable MRI workflow. By leveraging the NVIDIA advanced suite of training and inference tools, such as NVIDIA DALI and MONAI, the collaboration seeks to further improve the Swoop® system’s image quality, reduce scan times, and enable faster, more reliable diagnoses.
“Our mission is to make portable brain imaging faster, more intelligent, and increasingly accessible—ultimately improving health outcomes and reducing costs globally,” said Maria Sainz, President and CEO of Hyperfine, Inc. “Partnering with NVIDIA presents an incredible opportunity to advance and accelerate our AI technology. I’m thrilled about the possibilities this collaboration brings for the future.”
For more information about the Swoop® Portable MR Imaging® system, please visit hyperfine.io.
1) World Health Organization. Over 1 in 3 people affected by neurological conditions: The leading cause of illness and disability worldwide. World Health Organization. Published March 14, 2024. Accessed March 13, 2025. https://www.who.int/news/item/14-03-2024-over-1-in-3-people-affected-by-neurological-conditions–the-leading-cause-of-illness-and-disability-worldwide
2) Ghotbi N, Taki M, Mehrabian F, Alavi N, Khorrami S. Artificial intelligence in stroke imaging: Advances, limitations, and future directions. J Stroke Cerebrovasc Dis. 2023;32(1):106969. doi:10.1016/j.jstrokecerebrovasdis.2022.106969
About the Swoop® Portable MR Imaging® System
The Swoop® Portable MR Imaging® system is U.S. Food and Drug Administration (FDA) cleared for brain imaging of patients of all ages. It is a portable, ultra-low-field magnetic resonance imaging device for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis. The Swoop® system is also CE marked in the European Union and is UKCA marked in the United Kingdom. The Swoop® system is commercially available in a select number of international markets.
About Hyperfine, Inc.
Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop® system—the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. For more information, visit hyperfine.io.
The Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Actual results of Hyperfine, Inc. (the “Company”) may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s goals and commercial plans, the benefits of the Company’s products and services, and the Company’s future performance and its ability to implement its strategy. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company’s product development and commercialization activities, including the degree that the Swoop® system is accepted and used by healthcare professionals; the impact of COVID-19 on the Company’s business; the inability to maintain the listing of the Company’s Class A common stock on the Nasdaq; the Company’s inability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company’s products and services and reimbursement for medical procedures conducted using the Company’s products and services; the Company’s estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties indicated from time to time in Company’s filings with the Securities and Exchange Commission, including those under “Risk Factors” therein. The Company cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
Media Contact
Devin Zell
Hyperfine
dzell@hyperfine.io
Investor Contact
Webb Cambell
Gilmartin Group LLC
webb@gilmartinir.com
Media Contact
Devin Zell
Hyperfine
dzell@hyperfine.io
Investor Contact
Webb Cambell
Gilmartin Group LLC
webb@gilmartinir.com
Media Contact
Devin Zell
Hyperfine
dzell@hyperfine.io
Investor Contact
Webb Cambell
Gilmartin Group LLC
webb@gilmartinir.com
© 2025 Business Wire, Inc.
